Dermatology Practice EBITDA Multiples: 4x–7x — What Buyers Pay (2026)
Independent dermatology practices are trading at 4x–7x EBITDA. Cosmetic revenue mix, provider depth, and payer diversification are the key valuation levers.
Dermatology practices are among the most acquisitive specialties in lower middle market healthcare M&A, driven by private equity roll-up demand and favorable demographics. Practices with $1M–$5M revenue typically trade at 4x–7x EBITDA, with premium multiples reserved for those combining strong cosmetic cash-pay revenue with multi-provider clinical teams and diversified payer contracts.
Dermatology Practice EBITDA Multiples (2026)
| Practice Size | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Solo Physician, Medical-Only | $300K–$600K | 4x–5x | High key-person risk with single MD driving 80%+ of revenue. Limited cosmetic mix. Often structured with SBA financing and seller transition period. |
| Small Group, Mixed Revenue | $600K–$1M | 5x–6x | 2+ providers with some cosmetic revenue. Moderate payer diversification. Attractive to physician entrepreneurs and smaller PE platforms. |
| Established Multi-Provider Practice | $1M–$2M | 6x–7x | Strong cosmetic and medical revenue split, recurring patient base, modern EMR. Prime target for dermatology roll-up platforms with equity rollover structures. |
| Platform-Ready Group Practice | $2M+ | 7x+ | Multiple locations or high-volume single site with PA/NP leverage. Scalable infrastructure and clean malpractice history command top-of-range premiums. |
Valuation Drivers — What Makes Your Multiple Higher or Lower
The spread between 3.5x and 6.5x is not random. These seven factors determine where your firm lands.
Cosmetic Revenue Mix
High PositiveBotox, fillers, and laser services carry 60–70% margins and are cash-pay, significantly increasing EBITDA quality and buyer demand compared to insurance-dependent medical revenue.
Provider Depth and Key-Person Risk
High Positive or NegativePractices with 2+ licensed dermatologists or strong PA/NP support reduce key-person dependency, a critical concern for buyers underwriting physician retention post-acquisition.
Payer Mix and Reimbursement Stability
ModeratePractices with less than 40% Medicare concentration and strong commercial contracts command higher multiples due to reduced exposure to reimbursement rate compression.
Malpractice History and Compliance
High Negative if PoorUnresolved malpractice claims, state medical board actions, or gaps in tail coverage are deal-killers that suppress multiples or derail transactions entirely.
EMR Infrastructure and Revenue Cycle Quality
Moderate PositiveModern practice management software with clean billing and collections history reduces integration costs for acquirers and supports higher confidence in normalized EBITDA.
Recent Market Trends
PE-backed dermatology platforms continue aggressive roll-up activity, pushing multiples toward the higher end of the 6x–7x range for platform-quality practices. Cosmetic revenue streams, particularly injectables, are commanding premium valuations. MSO structures are increasingly standard to navigate corporate practice of medicine compliance across states.
Who Buys Dermatology Practices in 2026
Individual Operator / Search Fund
Entrepreneurship through acquisition (ETA), first-time buyers, industry-adjacent operators
What they want: Stable, transferable cash flow in a Dermatology Practice. SBA-eligible business, strong cosmetic revenue mix, and a seller available for a 12–18 month transition.
Pros for seller
- +SBA 7(a) financing means 10% buyer equity — faster than waiting for institutional capital
- +Buyer works inside the business, maintaining client and staff relationships
- +Deal structure is typically straightforward: cash at close plus seller note
Cons for seller
- −Lower multiples than PE buyers — typically at the low-to-mid end of the range
- −Requires meaningful seller involvement post-close for transition
- −SBA approval timeline adds 60–90 days to closing
PE-Backed Roll-Up Platform
Private equity consolidators building a Dermatology Practice portfolio, regional or national platforms
What they want: Scale, operational quality, and geographic coverage. Strong cosmetic revenue mix with minimal provider depth and key-person risk. Clean financials, documented systems, and staff who can operate without the selling owner.
Pros for seller
- +All-cash close with no SBA financing contingency or approval delay
- +Highest multiples available for premium businesses
- +Equity rollover option — seller keeps 10–30% stake and participates in platform exit
Cons for seller
- −Extensive 90–150 day due diligence process
- −Post-close integration into a larger platform changes operating culture
- −Usually requires seller to remain in a leadership role for 12–24 months
Strategic Acquirer
Larger Dermatology Practice operators, adjacent-industry buyers adding capacity or geography
What they want: Client relationships, staff, and market position that complement existing operations. Cosmetic Revenue Mix is especially valuable when it fills a gap the buyer cannot build organically.
Pros for seller
- +Can pay above-model multiples for strong strategic fit
- +Buyer already understands the business — diligence moves faster
- +Shorter transition requirement when operational overlap exists
Cons for seller
- −Fewer competing buyers — less negotiating leverage
- −Non-compete scope is typically broader than PE or individual deals
- −Operations and brand may change significantly post-close
Sample Dermatology Practice Transactions
Solo dermatologist with growing Botox/filler program and 1 PA in suburban Southeast market. Clean malpractice history, 3-year lease renewal secured.
$550K
EBITDA
5.2x
Multiple
$2.86M
Price
Two-physician group with 35% cosmetic revenue, diversified commercial payer mix, and modern EMR in mid-size Midwest metro. Minimal Medicare dependency.
$980K
EBITDA
6.1x
Multiple
$5.98M
Price
Three-provider practice with two locations, strong aesthetic program, and PA leverage. Targeted by regional dermatology roll-up platform with equity rollover.
$1.8M
EBITDA
6.8x
Multiple
$12.24M
Price
EBITDA Valuation Estimator
Get your Dermatology Practice business value range instantly
Industry: Dermatology Practice · Multiples based on 5x–6x (Small Group, Mixed Revenue)
Powered by DealFlow OS
dealflow-os.com · Free M&A tools for every stage of the deal
How to Use These Multiples
For Sellers: 4-Step Valuation Walkthrough
- 1
Compile three years of P&L statements and tax returns that reconcile line by line — SBA lenders and institutional buyers both require this, and any unexplained gap triggers diligence delays or price renegotiation.
- 2
Build a normalized EBITDA schedule with every add-back documented: owner W-2 above a market-rate manager salary, personal expenses, one-time items, and non-recurring costs. Undocumented add-backs get cut.
- 3
Address your provider depth and key-person risk before going to market — this is the most common reason Dermatology Practice businesses receive offers at the low end of the 4x–7x range. Buyers identify it in diligence and reprice accordingly.
- 4
Quantify and document your cosmetic revenue mix with supporting records: contracts, renewal histories, and client revenue breakdowns. This is the primary evidence for commanding a premium multiple — have it ready before the first buyer call.
For Buyers: Validate the Asking Multiple
- 1
Request trailing 12-month and 3-year P&L with bank statement backup before making an offer. If a Dermatology Practice seller cannot produce reconciled financials, that signals what the full diligence process will look like.
- 2
Verify the cosmetic revenue mix claims independently — pull contract copies, renewal documentation, and client-level revenue data. This is the primary driver of whether this Dermatology Practice is worth 7x or 4x.
- 3
Assess provider depth and key-person risk directly: ask which revenue or client relationships depend on the current owner personally, and what the transition plan is. An exit-ready seller has already worked through this.
- 4
Model your SBA debt service against verified EBITDA before signing the LOI. At current rates, a $1M SBA 7(a) loan runs approximately $13,000/month over 10 years — the business needs at least 1.25x debt service coverage after a market-rate manager salary.
Frequently Asked Questions
What EBITDA multiple should I expect when selling my dermatology practice?
Most independent dermatology practices sell at 4x–7x EBITDA. Practices with strong cosmetic revenue, multiple providers, and clean compliance records achieve the upper range of 6x–7x.
Does cosmetic revenue increase my dermatology practice valuation?
Yes significantly. Cash-pay cosmetic services like Botox and laser treatments carry higher margins than insurance-reimbursed procedures, improving EBITDA quality and attracting premium multiples from PE buyers.
Can I use an SBA loan to buy a dermatology practice?
Yes. Dermatology practices are SBA 7(a) eligible. Buyers commonly combine SBA financing with a seller note covering 10–15% of purchase price and a 12–24 month seller transition period.
How does physician retention risk affect dermatology practice multiples?
It's one of the top valuation concerns. Practices where one physician drives 80%+ of revenue face multiple compression and heavy earnout structures until buyer confidence in retention is established.
More Dermatology Practice Guides
Related Reading
Find Dermatology Practice businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
No credit card required